BACKGROUND/AIM: A possible role of antibody-drug conjugates against tumors with low HER2-expression, leads to the emergence of a new "low-HER2" classification in breast cancer, encompassing tumors from the hormonal-receptor-positive and the triple-negative subgroups. There is a need for data (clinical trial data and real-world evidence) that will accurately describe this population, the risk of recurrence and the possible benefit of HER2 targeted therapies. PATIENTS AND METHODS: We retrospectively analyzed 949 patients from our Department databases, with hormonal receptor-positive and HER2-negative early breast cancer, for whom detailed data for immunohistochemical HER2-staining could be retrieved. RESULTS: HER2-low expression was detected in 66.6% of patients (472 IHC +1 and 160 IHC +2 and ISH-negative). Lobular, or mixed lobular and ductal cancers had a statistically significantly lower chance of being HER2-low when compared to pure infiltrative ductal carcinomas (53.1% vs. 69.3% respectively). HER2-low status was not prognostic for recurrence-free survival or response to neoadjuvant chemotherapy. There was a non-significant trend for increased risk of recurrence for HER2-low, compared to HER2-0, in patients with lobular or mixed lobular and ductal carcinomas (HR=2.192, 95% CI=0.819-5.912). CONCLUSION: Low expression of HER2 in hormonal receptor-positive early breast cancer does not affect prognosis but may lead to a shorter progression-free-survival in lobular and mixed ductal and lobular cancers. Despite optimal management, a large proportion of hormonal receptor-positive patients will relapse. Targeting HER2 in HER2-low cancers may offer a potential additional treatment strategy to improve survival of this group. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: A possible role of antibody-drug conjugates against tumors with low HER2-expression, leads to the emergence of a new "low-HER2" classification in breast cancer, encompassing tumors from the hormonal-receptor-positive and the triple-negative subgroups. There is a need for data (clinical trial data and real-world evidence) that will accurately describe this population, the risk of recurrence and the possible benefit of HER2 targeted therapies. PATIENTS AND METHODS: We retrospectively analyzed 949 patients from our Department databases, with hormonal receptor-positive and HER2-negative early breast cancer, for whom detailed data for immunohistochemical HER2-staining could be retrieved. RESULTS: HER2-low expression was detected in 66.6% of patients (472 IHC +1 and 160 IHC +2 and ISH-negative). Lobular, or mixed lobular and ductal cancers had a statistically significantly lower chance of being HER2-low when compared to pure infiltrative ductal carcinomas (53.1% vs. 69.3% respectively). HER2-low status was not prognostic for recurrence-free survival or response to neoadjuvant chemotherapy. There was a non-significant trend for increased risk of recurrence for HER2-low, compared to HER2-0, in patients with lobular or mixed lobular and ductal carcinomas (HR=2.192, 95% CI=0.819-5.912). CONCLUSION: Low expression of HER2 in hormonal receptor-positive early breast cancer does not affect prognosis but may lead to a shorter progression-free-survival in lobular and mixed ductal and lobular cancers. Despite optimal management, a large proportion of hormonal receptor-positive patients will relapse. Targeting HER2 in HER2-low cancers may offer a potential additional treatment strategy to improve survival of this group. Copyright 2022, International Institute of Anticancer Research.
Entities:
Keywords:
Breast cancer; HER2-low; Hormone Receptor positive; lobular; prognosis
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Diana Flores-Díaz; Claudia Arce; Lourdes Flores-Luna; Nancy Reynoso-Noveron; Fernando Lara-Medina; Juan Antonio Matus; Enrique Bargallo-Rocha; Víctor Pérez; Cynthia Villarreal-Garza; Paula Cabrera-Galeana; Alejandro Mohar Journal: Breast Cancer Res Treat Date: 2019-04-17 Impact factor: 4.872
Authors: Carsten Denkert; Fenja Seither; Andreas Schneeweiss; Theresa Link; Jens-Uwe Blohmer; Marianne Just; Pauline Wimberger; Almuth Forberger; Hans Tesch; Christian Jackisch; Sabine Schmatloch; Mattea Reinisch; Erich F Solomayer; Wolfgang D Schmitt; Claus Hanusch; Peter A Fasching; Kristina Lübbe; Christine Solbach; Jens Huober; Kerstin Rhiem; Frederik Marmé; Toralf Reimer; Marcus Schmidt; Bruno V Sinn; Wolfgang Janni; Elmar Stickeler; Laura Michel; Oliver Stötzer; Eric Hahnen; Jenny Furlanetto; Sabine Seiler; Valentina Nekljudova; Michael Untch; Sibylle Loibl Journal: Lancet Oncol Date: 2021-07-09 Impact factor: 41.316
Authors: Michael Z Gilcrease; Wendy A Woodward; Marlo M Nicolas; Lynda J Corley; Gregory N Fuller; Francisco J Esteva; Susan L Tucker; Thomas A Buchholz Journal: Am J Surg Pathol Date: 2009-05 Impact factor: 6.394
Authors: George Douganiotis; George Kesisis; Efthalia Lalla; Ippokratis Korantzis; Ioannis Boukovinas; Konstantinos Papazisis Journal: Cancer Diagn Progn Date: 2022-09-03